CD276 and neoplasm: In conclusion, the trispecific B7-H3xCD16xTIGIT NK cell engager combines tumor cell targeting by B7-H3 binding, NK checkpoint inhibition by TIGIT binding, and NK cell activation by CD16 binding in one molecule.